Abstract:Breast cancer (BC), characterized by its diverse molecular profiles and clinical outcomes, presents a significant challenge in the development of effective therapeutic strategies. Metabolic reprogramming, a defining characteristic of cancer, has emerged as a promising target for novel therapies. SLC7A11, an amino acid transporter that facilitates cysteine uptake in exchange for glutamate, plays a crucial role in sustaining the altered metabolism of cancer cells. This study delves into the comprehensive analysis of SLC7A11 at the genomic, transcriptomic, and protein levels in extensive BC datasets to elucidate its potential role in different BC subtypes. SLC7A11 gene copy number and mRNA expression were evaluated using the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohort (n = 1,980) and Breast Cancer Gene Expression Miner (n = 4,712). SLC7A11 protein was assessed using immunohistochemistry in a large BC cohort (n = 1,981). Additionally, The Cancer Genome Atlas (TCGA) dataset was used to explore SLC7A11 DNA methylation patterns using MethSurv (n = 782) and association of SLC7A11 mRNA expression with immune infiltrates using TIMER (n = 1,100). High SLC7A11 mRNA and SLC7A11 protein expression were significantly associated with high tumor grade (p ≤ .02), indicating a potential role in cancer progression. Interestingly, SLC7A11 copy number gain was observed in HER2+ tumors (p = .01), suggesting a subtype-specific association. In contrast, SLC7A11 mRNA expression was higher in the basal-like/triple-negative (TN; p < .001) and luminal B tumors (p = .02), highlighting its differential expression across BC subtypes. Notably, high SLC7A11 protein expression was predominantly observed in Estrogen Receptor (ER)-negative and Triple Negative (TN) BC, suggesting a role in these aggressive subtypes. Further analysis revealed that SLC7A11 was positively correlated with other amino acid transporters and enzymes associated with glutamine metabolism, implying a coordinated role in metabolic regulation. Additionally, SLC7A11 gene expression was positively associated with neutrophil and macrophage infiltration, suggesting a potential link between SLC7A11 and tumor immunity. Our findings suggest that SLC7A11 plays a significant role in BC metabolism, demonstrating differential expression across subtypes and associations with poor patient outcomes. Further functional studies are warranted to elucidate the precise mechanisms by which SLC7A11 contributes to BC progression and to explore its potential as a therapeutic target.

SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma

SLC7A11/xCT in Cancer: Biological Functions and Therapeutic Implications.

High expression of cystine–glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma

Elevated SLC3A2 associated with poor prognosis and enhanced malignancy in gliomas

Chloride Intracellular Channel 1 Cooperates with Potassium Channel EAG2 to Promote Medulloblastoma Growth.

GSE1 Predicts Poor Survival Outcome in Gastric Cancer Patients by SLC7A5 Enhancement of Tumor Growth and Metastasis.

SLC39A1 contribute to malignant progression and have clinical prognostic impact in gliomas

Overexpression of SLC7A7 predicts poor progression-free and overall survival in patients with glioblastoma

The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer

The Role of SLC7A11 in Cancer: Friend or Foe?

TMET-29. THE GLUTAMINE TRANSPORTER SLC1A5 IS ASSOCIATED WITH REWIRING OF AMINO ACID, LIPID, AND IMMUNE PATHWAYS AND TUMOR PROGNOSIS IN PEDIATRIC BRAIN CANCERS

The amino acid transporter SLC7A11-mediated crosstalk implicated in cancer therapy and the tumor microenvironment

SLC39A7 promotes malignant behaviors in glioma via the TNF-α-mediated NF-κB signaling pathway

SLC11A1 As a Stratification Indicator for Immunotherapy or Chemotherapy in Patients with Glioma

Compromised Glutamate Transport in Human Glioma Cells: Reduction–Mislocalization of Sodium-Dependent Glutamate Transporters and Enhanced Activity of Cystine–Glutamate Exchange

Cystine Transporter Regulation of Pentose Phosphate Pathway Dependency and Disulfide Stress Exposes a Targetable Metabolic Vulnerability in Cancer

Genetic variants in SLC7A7 are associated with risk of glioma in a Chinese population.

Whole Exome-Wide Association Study Identifies a Missense Variant in SLC2A4RG Associated with Glioblastoma Risk

Shuttling SLC2A4RG is Regulated by 14-3-3θ to Modulate Cell Survival Via Caspase-3 and Caspase-6 in Human Glioma

Induction of glioblastoma invasion triggered by system Xc−-mediated glutamate release

The amino acid transporter SLC7A11 expression in breast cancer